Waters Corporation (WAT)
WAT trades on NYSE in Industrials, Biotechnology: Laboratory Analytical Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1000697/000119312526062604/0001193125-26-062604-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | WAT on NYSE |
| Sector | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments |
| Country | United States |
| IPO year | 1995 |
| SEC CIK | 0001000697 |
| SEC industry code | Laboratory Analytical Instruments |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $3.2B |
| Net income | $642.6M |
| Operating income | $802.6M |
| Net margin | 20.3% |
| Operating margin | 25.4% |
| Revenue growth | +7.0% |
| Cash | $587.8M |
| Total assets | $5.1B |
| P/E (computed) | 69.3× |
| P/S (computed) | 14.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-10 |
| Cash and burn | $593.0M cash; operating cash flow $119.9M a quarter. | Report 2026-10-03 |
| Shares outstanding | 98,285,634 (2026-11-06); 59,534,740 a year earlier; 59,126,977 three years earlier. | Cover page 2026-11-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-03-16 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $451K, sold $1.4M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-10-03 | $1.8B | $81.0M | $117.0M | $593.0M | $4.5B | $5.6B | 10-Q 2026-11-10 |
| Q2 2026 2026-07-04 | $1.6B | -$136.0M | $201.0M | $539.0M | $4.9B | $4.6B | 10-Q 2026-08-11 |
| Q1 2026 2026-04-04 | $1.3B | -$72.0M | -$3.0M | $462.0M | $4.9B | Needs four quarters | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $932.4M | $225.6M | $164.6M | $588.0M | $1.4B | $3.2B | 10-K 2026-02-23 |
| Q3 2025 2025-09-30 | $799.9M | $148.9M | Not filed | $459.1M | $947.2M | Needs four quarters | 10-K 2026-02-23 |
| Q3 2025 2025-09-27 | $800.0M | $149.0M | $187.0M | $459.1M | $947.2M | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $771.3M | $147.1M | Not filed | $367.2M | $1.2B | Needs four quarters | 10-K 2026-02-23 |
| Q2 2025 2025-06-28 | $771.0M | $147.0M | $41.0M | $367.2M | $1.2B | Needs four quarters | 10-Q 2026-08-11 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B2 | 2026-03-19 |
| Latest annual report | 10-K | 2026-02-23 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEFA14A | 2026-04-09 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.6% |
| 1 month | +7.2% |
| 3 months | +11.3% |
| Year to date | +21.2% |
| 1 year | +21.3% |
| From 52-week high | -4.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Laboratory Analytical Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| A | Agilent Technologies Inc. | $172.92 | -0.60% | $48.8B |
| MTD | Mettler-Toledo International Inc. | $1727.26 | -0.67% | $34.4B |
| RVTY | Revvity Inc. | $148.85 | -3.59% | $16.6B |
| AVTR | Avantor Inc. | $15.32 | -1.42% | $10.4B |
| BIO | Bio-Rad Laboratories Inc. | $360.26 | -1.67% | $9.7B |
| BRKR | Bruker Corporation | $60.62 | -1.57% | $9.3B |
| TXG | 10x Genomics Inc. | $54.99 | -5.50% | $7.2B |
| ALMR | Alamar Biosciences Inc. | $30.55 | -0.84% | $2.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier